550 related articles for article (PubMed ID: 3053124)
41. Gastric mucosa protection and prostaglandin E2 generation in rats by colloidal bismuth subcitrate (DE-NOL).
Hall DW; van den Hoven WE
Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):308-19. PubMed ID: 3473983
[TBL] [Abstract][Full Text] [Related]
42. Ranitidine bismuth citrate: a novel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture.
McColm AA; McLaren A; Klinkert G; Francis MR; Connolly PC; Grinham CJ; Campbell CJ; Selway S; Williamson R
Aliment Pharmacol Ther; 1996 Jun; 10(3):241-50. PubMed ID: 8791946
[TBL] [Abstract][Full Text] [Related]
43. [Bismuth revisited in Helicobacter pylori gastro-duodenal infection].
Caron F; Rouveix B
Therapie; 1991; 46(5):393-8. PubMed ID: 1754987
[TBL] [Abstract][Full Text] [Related]
44. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.
Marshall BJ; Goodwin CS; Warren JR; Murray R; Blincow ED; Blackbourn SJ; Phillips M; Waters TE; Sanderson CR
Lancet; 1988 Dec 24-31; 2(8626-8627):1437-42. PubMed ID: 2904568
[TBL] [Abstract][Full Text] [Related]
45. Colloidal bismuth subcitrate, ranitidine, and ranitidine plus metronidazole in the treatment of duodenal ulcer and Helicobacter pylori infection: a controlled and prospective study.
Huang CK; Chen GH
Zhonghua Yi Xue Za Zhi (Taipei); 1993 Jul; 52(1):15-20. PubMed ID: 8364776
[TBL] [Abstract][Full Text] [Related]
46. Campylobacter pylori and ulcer disease--a causal connection?
Wormsley KG
Scand J Gastroenterol Suppl; 1989; 160():53-8. PubMed ID: 2683023
[TBL] [Abstract][Full Text] [Related]
47. Lansoprazole: an update of its place in the management of acid-related disorders.
Matheson AJ; Jarvis B
Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
[TBL] [Abstract][Full Text] [Related]
48. Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of colloidal bismuth subcitrate (De-Nol).
Morris A; Brown P; Ali MR; Lane M; Palmer R
N Z Med J; 1988 Oct; 101(856 Pt 1):651-4. PubMed ID: 3054641
[TBL] [Abstract][Full Text] [Related]
49. Maintenance therapy with colloidal bismuth subcitrate in duodenal ulcer disease.
Bianchi Porro G; Lazzaroni M; Cortvriendt WR
Digestion; 1987; 37 Suppl 2():47-52. PubMed ID: 3305118
[TBL] [Abstract][Full Text] [Related]
50. The influence of colloidal bismuth subcitrate on duodenal ulcer relapse.
Bianchi Porro B; Lazzaroni M; Parente F; Petrillo M
Scand J Gastroenterol Suppl; 1986; 122():35-8. PubMed ID: 3535020
[TBL] [Abstract][Full Text] [Related]
51. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.
Liu CC; Lee CL; Chan CC; Tu TC; Liao CC; Wu CH; Chen TK
Arch Intern Med; 2003 Sep; 163(17):2020-4. PubMed ID: 14504114
[TBL] [Abstract][Full Text] [Related]
52. Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).
Tefera S; Berstad A; Bang CJ; Nysaeter G; Hatlebakk JG; Olafsson S; Nesje LB; Hausken T; Berstad K; Hundal O
Am J Gastroenterol; 1996 May; 91(5):935-41. PubMed ID: 8633584
[TBL] [Abstract][Full Text] [Related]
53. Bismuth absorption from 205Bi-labelled pharmaceutical bismuth compounds used in the treatment of peptic ulcer disease.
Dresow B; Fischer R; Gabbe EE; Wendel J; Heinrich HC
Scand J Gastroenterol; 1992 Apr; 27(4):333-6. PubMed ID: 1589712
[TBL] [Abstract][Full Text] [Related]
54. Misoprostol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.
Monk JP; Clissold SP
Drugs; 1987 Jan; 33(1):1-30. PubMed ID: 3102205
[TBL] [Abstract][Full Text] [Related]
55. Enprostil. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.
Goa KL; Monk JP
Drugs; 1987 Nov; 34(5):539-59. PubMed ID: 3121276
[TBL] [Abstract][Full Text] [Related]
56. Colloidal bismuth subcitrate and omeprazole inhibit alcohol dehydrogenase mediated acetaldehyde production by Helicobacter pylori.
Roine RP; Salmela KS; Höök-Nikanne J; Kosunen TU; Salaspuro M
Life Sci; 1992; 51(21):PL195-200. PubMed ID: 1435071
[TBL] [Abstract][Full Text] [Related]
57. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.
Goodwin CS; Marshall BJ; Blincow ED; Wilson DH; Blackbourn S; Phillips M
J Clin Pathol; 1988 Feb; 41(2):207-10. PubMed ID: 3280609
[TBL] [Abstract][Full Text] [Related]
58. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
Kung NN; Sung JJ; Yuen NW; Ng PW; Wong KC; Chung EC; Lim BH; Choi CH; Li TH; Ma HC; Kwok SP
Am J Gastroenterol; 1997 Mar; 92(3):438-41. PubMed ID: 9068464
[TBL] [Abstract][Full Text] [Related]
59. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease.
Graham DY; Hepps KS; Ramirez FC; Lew GM; Saeed ZA
Scand J Gastroenterol; 1993 Nov; 28(11):939-42. PubMed ID: 8284627
[TBL] [Abstract][Full Text] [Related]
60. Pharmacology of bismuth-containing compounds.
Lambert JR
Rev Infect Dis; 1991; 13 Suppl 8():S691-5. PubMed ID: 1925310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
